| Drug Name |
Riluzole |
| Drug ID |
BADD_D01942 |
| Description |
A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi. |
| Indications and Usage |
For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease) |
| Marketing Status |
Prescription |
| ATC Code |
N07XX02 |
| DrugBank ID |
DB00740
|
| KEGG ID |
D00775
|
| MeSH ID |
D019782
|
| PubChem ID |
5070
|
| TTD Drug ID |
D0H0KB
|
| NDC Product Code |
70515-700; 35709-0003; 10094-350; 42291-775; 65129-1011; 63537-0066; 62756-983; 70726-0303; 68462-381; 0378-4145; 62756-538; 67877-286; 69076-200; 65977-0045; 63278-1076; 66039-812; 70510-2201 |
| Synonyms |
Riluzole | 2-Amino-6-trifluoromethoxybenzothiazole | 2 Amino 6 trifluoromethoxybenzothiazole | Rilutek | RP-54274 | RP 54274 | RP54274 | PK-26124 | PK 26124 | PK26124 |
